background
acut
lower
respiratori
infect
commonest
caus
morbid
potenti
prevent
mortal
indigen
infant
infanc
also
critic
time
postnat
lung
growth
develop
sever
repeat
lower
airway
injuri
young
children
like
increas
likelihood
chronic
pulmonari
disord
later
life
global
bronchiol
common
form
acut
lower
respiratori
infect
infanc
compar
nonindigen
australian
infant
indigen
infant
greater
bacteri
densiti
upper
airway
sever
bronchiol
episod
studi
test
hypothesi
antimicrobi
antiinflammatori
properti
azithromycin
improv
clinic
outcom
indigen
australian
infant
hospitalis
bronchiol
conduct
dual
centr
randomis
doubleblind
placebocontrol
parallel
group
trial
northern
australia
indigen
infant
age
expect
number
admit
one
two
region
hospit
darwin
northern
territori
townsvil
queensland
clinic
diagnosi
bronchiol
fulfil
inclus
criteria
randomis
alloc
conceal
either
azithromycin
mgkgdose
placebo
administ
weekli
three
dose
clinic
data
record
twice
daili
nasopharyng
swab
collect
enrol
time
discharg
hospit
primari
outcom
length
oxygen
requir
durat
stay
latter
base
upon
judg
readi
respiratori
discharg
main
secondari
outcom
readmiss
respiratori
ill
within
leav
hospit
descript
virolog
bacteriolog
includ
develop
antibiot
resist
data
nasopharyng
sampl
also
report
discuss
two
publish
studi
involv
differ
patient
popul
set
well
differ
macrolid
antibiot
treatment
durat
produc
conflict
result
randomis
placebocontrol
trial
azithromycin
indigen
infant
hospitalis
bronchiol
design
determin
whether
reduc
shortterm
potenti
longterm
morbid
respiratori
ill
australian
indigen
infant
high
risk
develop
chronic
respiratori
ill
azithromycin
efficaci
reduc
morbidli
indigen
infant
hospitalis
bronchiol
intervent
would
lead
improv
short
term
possibl
long
term
health
benefit
trial
registr
australia
new
zealand
clinic
trial
regist
anzctr
background
worldwid
bronchiol
common
acut
lower
respiratori
tract
infect
alri
infant
northern
territori
nt
australia
alri
frequent
reason
hospitalis
young
children
age
alri
also
commonest
caus
prevent
death
indigen
infant
time
nonindigen
alri
bronchiol
without
pneumonia
frequent
reason
hospit
admiss
nt
indigen
infant
age
despit
heavi
burden
bronchiol
indigen
infant
current
prospect
studi
publish
retrospect
review
infant
hospitalis
bronchiol
royal
darwin
hospit
darwin
northern
territori
found
indigen
infant
readmit
within
sixmonth
discharg
hospit
retriev
remot
commun
impact
ill
cost
social
disloc
like
substanti
recurr
alri
independ
associ
develop
bronchiectasi
reduc
pulmonari
function
later
life
low
birth
weight
preexist
small
lung
import
determin
futur
lung
function
increas
evid
event
earli
life
least
equal
import
determin
adult
pulmonari
dysfunct
first
year
life
critic
period
thu
event
sever
alri
critic
period
like
long
term
effect
australiawid
hospitalis
rate
respiratori
disord
among
indigen
australian
second
renal
dialysi
furthermor
previous
document
sever
hospitalis
alri
episod
determin
oxygen
requir
durat
hospitalis
independ
risk
factor
subsequ
bronchiectasi
northern
territori
nt
bronchiectasi
affect
one
everi
indigen
children
far
exceed
cystic
fibrosi
cf
nonindigen
australian
children
thu
intervent
reduc
bronchiol
sever
andor
risk
readmiss
respiratori
ill
indigen
infant
may
short
term
potenti
long
term
benefit
set
bronchiol
characteris
extens
inflamm
airway
accompani
increas
mucou
product
necrosi
airway
epitheli
cell
paediatr
bronchiol
clinic
diagnosi
characteris
tachypnoea
wheez
andor
crepit
infant
follow
preced
upper
respiratori
ill
primarili
caus
infect
respiratori
epitheli
cell
varieti
virus
especi
respiratori
syncyti
viru
rsv
virus
adenoviru
influenza
parainfluenza
human
metapneumoviru
rhinoviru
also
implic
increasingli
new
virus
detect
associ
ill
addit
mycoplasma
pneumonia
chlamydia
speci
recognis
increasingli
import
contributor
develop
chronic
lung
diseas
alter
lung
matur
new
treatabl
bacteria
simkania
negevensi
chlamydialik
microb
found
canadian
inuit
infant
bronchiol
publish
data
natur
divers
respiratori
pathogen
associ
bronchiol
indigen
australian
infant
typic
antimicrobi
recommend
routin
manag
bronchiol
two
rct
macrolid
bronchiol
singl
avail
rct
nonmacrolid
antimicrobi
neg
studi
howev
set
sever
reason
antimicrobi
may
reduc
morbid
hospitalis
indigen
infant
bronchiol
colonis
nasopharynx
bacteria
known
risk
factor
childhood
pneumonia
indigen
infant
colonis
nasopharynx
earli
life
earli
age
colonis
also
dens
common
respiratori
bacteri
pathogen
notabl
streptococcu
pneumonia
haemophilu
infleunza
moraxella
catarrhali
repeat
microaspir
nasopharyng
secret
heavili
laden
pathogen
bacteria
alri
may
overwhelm
alreadi
compromis
pulmonari
defenc
increas
risk
secondari
pneumonia
lower
airway
infect
inde
indigen
infant
like
receiv
antibiot
episod
pneumonia
diagnos
admiss
bronchiol
nonindigen
infant
nurs
paediatr
unit
macrolid
class
antibiot
contain
macrocycl
lacton
ring
excel
tissu
penetr
antimicrobi
activ
broad
rang
gram
posit
gram
neg
bacteria
includ
intracellular
pathogen
chlamydia
lacton
ring
also
sever
nonantimicrobi
properti
studi
extens
invitro
experiment
model
lesser
extent
human
one
effect
modul
immun
respons
immun
modul
properti
macrolid
make
attract
candid
treat
inflammatori
airway
diseas
two
publish
placebocontrol
rct
macrolid
rsvbronchiol
report
contradictori
result
small
turkish
studi
hospitalis
infant
moder
sever
bronchiol
daili
clarithromycin
significantli
reduc
sever
ill
oxygen
use
hospit
stay
risk
hospit
readmiss
respiratori
ill
next
month
howev
anoth
larger
studi
involv
infant
netherland
azithromycin
efficaci
infant
hospitalis
bronchiol
differ
outcom
seen
two
trial
may
relat
dose
length
treatment
chanc
heterogen
studi
popul
infant
turkey
like
concomit
bacteri
infect
compar
affluent
european
group
moreov
turkey
postinfecti
childhood
bronchiectasi
remain
import
health
problem
popul
also
differ
age
european
studi
includ
infant
age
wherea
turkish
studi
involv
infant
age
clearli
well
design
rct
efficaci
macrolid
reduc
burden
bronchiol
popul
high
risk
acut
chronic
respiratori
diseas
would
benefici
primari
research
question
amongst
hospitalis
indigen
infant
bronchiol
azithromycin
compar
placebo
improv
clinic
outcom
length
stay
hospit
durat
oxygen
supplement
primari
hypothesi
antimicrobi
antiinflammatori
properti
macrolid
azithromycin
improv
clinic
outcom
indigen
infant
hospitalis
bronchiol
secondari
aim
determin
effect
azithromycin
readmiss
hospit
within
month
treatment
assess
shortterm
impact
azithromycin
macrolid
resist
pattern
respiratori
bacteri
pathogen
nasopharynx
describ
point
preval
divers
respiratori
virus
mycoplasma
pneumonia
chlamydia
speci
use
sensit
molecular
diagnost
techniqu
conduct
parallel
group
doubleblind
placebo
rct
conceal
alloc
assess
impact
addit
treatment
azithromycin
indigen
infant
admit
two
region
hospit
darwin
northern
territori
townsvil
queensland
bronchiol
studi
plan
summaris
figur
inclus
criteria
baselin
data
indigen
infant
age
admit
one
hospit
darwin
townsvil
clinic
diagnosi
bronchiol
absenc
intern
standardis
diagnosi
bronchiol
accept
australian
clinic
diagnosi
use
tachypnoea
respiratori
rate
infant
age
month
month
wheez
crackl
recruit
consent
within
present
hospit
ill
exclus
criteria
admiss
intens
care
macrolid
therapi
contraind
eg
liver
dysfunct
hypersensit
presenc
diarrhoea
stool
increas
wateri
consist
two
stool
usual
stool
frequenc
receiv
macrolid
last
clinic
radiolog
featur
consist
primari
diagnosi
pneumonia
time
randomis
site
sitespecif
studi
nurs
visit
ward
twice
daili
screen
newli
admit
infant
standardis
collect
form
use
collect
clinic
data
see
hospit
outcom
associ
bronchiol
episod
infant
manag
accord
standardis
protocol
use
royal
darwin
hospit
sinc
protocol
outlin
supplementari
oxygen
prescrib
reduc
nasogastr
feed
intraven
fluid
use
enrol
infant
may
receiv
addit
therapi
macrolid
discret
attend
paediatrician
elig
fulfil
inform
consent
obtain
infant
randomis
receiv
either
singl
oral
liquid
dose
azithromycin
syrup
mg
per
kg
equival
volum
placebo
medic
given
within
hospitalis
infant
randomis
intervent
arm
studi
receiv
addit
treatment
dose
azithromycin
syrup
mg
per
kg
randomis
control
arm
receiv
equival
volum
placebo
syrup
later
dose
either
supervis
studi
nurs
administ
famili
phone
support
day
medic
due
final
clinic
follow
occur
local
health
clinic
closest
avail
date
day
randomis
sequenc
comput
gener
use
permut
block
particip
per
block
alloc
sequenc
conceal
time
throughout
studi
comput
gener
alloc
perform
statistician
extern
studi
team
upon
enrol
infant
assign
next
number
appropri
stratifi
list
uniqu
number
assign
one
eight
treatment
alphabet
see
treatment
group
stratifi
age
month
site
darwin
townsvil
requir
ye
oxygen
point
randomis
import
exclud
older
children
stratifi
month
age
group
well
describ
placebo
medic
ensur
children
carer
research
hospit
staff
clinic
staff
blind
treatment
group
analys
data
placebo
medic
specif
manufactur
institut
drug
technolog
idt
australia
limit
melbourn
vic
similar
tast
colour
azithromycin
azithromycin
medic
repackag
idt
thu
azithromycin
placebo
ident
opaqu
bottl
seal
aluminium
foil
equal
volum
water
ad
use
syring
needl
punch
seal
eight
alphabet
n
p
q
r
u
use
bottl
azithromycin
placebo
medic
alphabet
use
multipl
alphabet
rather
sequenti
number
bottl
allow
storag
extra
bottl
trial
medic
clinic
dose
necessari
context
studi
set
children
mainli
remot
indigen
commun
enhanc
avail
administr
trial
medic
child
discharg
hospit
data
record
standardis
form
demograph
inform
age
gender
region
birth
detail
smoke
exposur
breast
feed
household
size
etc
medic
histori
obtain
primari
caregiv
medic
chart
primari
secondari
outcom
measur
see
monitor
twice
daili
hospit
admiss
endpoint
reach
readi
respiratori
discharg
defin
without
supplement
oxygen
infant
feed
well
clinic
assess
data
includ
oxygen
requir
level
physiolog
measur
clinic
sever
score
respiratori
rate
accessori
muscl
use
degre
wheez
physiolog
measur
temperatur
heart
rate
requir
durat
therapi
requir
intraven
fluid
nutrit
support
antibiot
ear
examin
find
sign
suppur
subsequ
pneumonia
diagnos
independ
treat
blind
paediatrician
addit
result
routin
investig
full
blood
count
chest
radiograph
find
record
presenc
cough
wheez
auscultatori
abnorm
clinic
review
document
advers
effect
vomit
diarrhoea
rash
also
document
singl
nasopharyng
swab
np
specimen
respiratori
viru
potenti
import
respiratori
pathogen
pneumonia
chlamydia
spp
test
collect
subject
enrol
addit
np
repeat
hospit
discharg
bacteri
cultur
antibiot
suscept
test
per
laboratori
research
protocol
see
cultur
identifi
serotyp
common
respiratori
bacteria
np
establish
techniqu
laboratori
menzi
darwin
swab
store
smggb
batch
process
typic
respiratori
bacteri
pathogen
notabl
h
influenza
nontyp
h
influenza
catarrhali
pneumonia
batch
swab
thaw
aliquot
cultur
overnight
select
media
co
growth
pneumonia
h
influenza
catarrhali
record
confirm
four
isol
pneumonia
h
influenza
two
isol
catarrhali
per
posit
swab
test
antimicrobi
resist
store
pneumonia
isol
serotyp
use
quellung
method
antisera
staten
serum
institut
denmark
addit
routin
suscept
test
use
calibr
dichotom
suscept
cd
disc
diffus
method
azithromycin
minimum
inhibitori
concentr
mic
determin
use
etest
ab
biodisk
sweden
azithromycin
disc
annulu
less
mm
pneumonia
penicillin
mic
determin
penicillin
nonsuscept
isol
oxacillin
andor
penicillin
disc
annulu
mm
h
influenza
ampicillin
mic
determin
isol
ampicillin
disc
annulu
less
mm
interpret
criteria
csli
breakpoint
use
pneumonia
penicillin
nonsuscept
mic
azithromycin
resist
mic
h
influenza
ampicillin
resist
mic
azithromycin
resist
mic
betalactamas
activ
determin
h
influenza
catarrhali
isol
previou
method
utilis
np
frozen
upon
thaw
nucleic
acid
extract
ml
np
specimen
use
high
pure
viral
nucleic
acid
kit
roch
diagnost
australia
accord
manufactur
instruct
monospecif
pcr
revers
transcriptas
pcr
rtpcr
method
use
detect
mycoplasma
pneumonia
coronavirus
bocaviru
human
metapneumoviru
hmpv
wherea
multiplex
pcr
rtpcr
use
detect
adenoviru
parainfluenza
influenza
b
respiratori
syncyti
viru
rsv
method
previous
valid
viral
laboratori
royal
children
hospit
brisban
particip
complet
outcom
obtain
exit
point
intoler
trial
medic
requir
withdraw
studi
deem
treat
paediatrician
directli
connect
studi
team
length
stay
lo
respiratori
ill
hospitaldefin
time
admiss
time
readi
discharg
respiratori
care
readi
discharg
mean
normox
consist
air
feed
adequ
ii
durat
supplement
oxygen
requir
readi
discharg
respiratori
care
differ
length
hospitalis
discharg
hospit
may
delay
social
transport
factor
especi
children
remot
commun
major
secondari
outcom
readmiss
respiratori
ill
within
discharg
hospit
minor
outcom
hospitalis
clinic
sever
score
addit
use
antibiot
episod
suppur
otiti
media
develop
pneumonia
outcom
presenc
cough
wheez
abnorm
auscultatori
chest
sign
suppur
otiti
media
also
analys
clinic
outcom
follow
predetermin
subgroup
age
ii
presenc
bacteri
respiratori
pathogen
resist
macrolid
antibiot
identif
respiratori
virus
bacteri
pathogen
ii
antibiot
resist
penicillin
macrolid
plan
enrol
indigen
infant
retrospect
studi
mean
lo
indigen
infant
bronchiol
rdh
sd
hour
mean
durat
supplement
oxygen
requir
indigen
infant
bronchiol
sd
hour
mean
differ
lo
group
power
requir
sampl
size
per
group
number
detect
differ
supplement
oxygen
requir
per
group
larg
effect
size
conserv
estim
seen
turkish
studi
studi
differ
group
lo
supplement
oxygen
requir
assum
similar
effect
sampl
size
least
subag
group
also
suffici
apriori
subgroup
analysi
base
age
power
effect
smaller
power
detect
differ
lo
infant
power
detect
differ
lo
age
group
believ
smaller
benefit
would
suffici
chang
clinic
practic
import
secondari
outcom
readmiss
rate
respiratori
ill
within
discharg
power
studi
detect
reduct
signific
larg
effect
consist
reduct
describ
turkish
studi
reduct
power
abl
detect
reduct
readmiss
rate
secondari
outcom
accur
sampl
size
estim
possibl
given
lack
relev
data
data
report
present
accord
updat
consort
criteria
children
analys
accord
alloc
statu
regardless
subsequ
manag
interim
analysi
plan
data
safeti
monitor
committe
determin
studi
ceas
superior
azithromycin
identifi
sampl
size
achiev
primari
outcom
lo
durat
supplement
oxygen
requir
compar
infant
receiv
placebo
azithromycin
use
unpair
student
ttest
mannwhitney
test
depend
normal
distribut
although
expect
randomis
equal
distribut
potenti
confound
factor
group
examin
distribut
known
confound
group
eg
birth
weight
smoke
exposur
statu
inutero
postnat
breast
feed
etc
baselin
data
differ
group
regress
use
check
primari
outcom
affect
chanc
find
apriori
subanalysi
compar
infant
age
age
examin
efficaci
azithromycin
reduc
readmiss
rate
respiratori
ill
secondari
odd
ratio
group
calcul
also
use
compar
addit
antibiot
use
group
number
need
treat
nnt
benefit
ci
describ
signific
differ
found
signific
nnt
harm
calcul
advers
event
secondari
shortterm
impact
azithromycin
macrolideresist
pathogen
np
cultur
proport
children
penicillinnonsuscept
pneumonia
macrolideresist
h
influenza
spp
catarrhali
trial
medic
compar
use
or
ci
descript
data
utilis
secondari
point
preval
respiratori
virus
respiratori
pathogen
acut
lower
respiratori
tract
infect
commonest
caus
hospitalis
potenti
prevent
death
indigen
infant
bronchiol
indigen
infant
sever
bronchiol
nonindigen
infant
higher
readmiss
rate
increas
risk
ongo
respiratori
morbid
includ
chronic
suppur
lung
diseas
indigen
infant
may
due
increas
likelihood
recurr
infect
virusbacteria
interact
earli
age
earli
age
along
heavi
bacteri
colonis
nasopharynx
despit
bronchiol
common
caus
alri
infant
result
hospitalis
publish
prospect
studi
ill
australian
indigen
infant
two
small
clinic
trial
studi
macrolid
bronchiol
contradictori
result
popul
set
close
relat
turkish
studi
benefici
effect
macrolid
shown
contrast
neg
find
dutch
studi
affluent
urban
set
propos
doubleblind
rct
determin
azithromycin
effect
addit
treatment
indigen
infant
hospitalis
bronchiol
also
determin
whether
ensu
month
prevent
hospit
readmiss
respiratori
ill
potenti
reduc
likelihood
chronic
lung
dysfunct
highrisk
popul
azithromycin
chosen
macrolid
prompt
potent
antiinflammatori
effect
well
hour
halflif
children
permit
weekli
dose
possibl
antivir
effect
also
attract
import
safeti
compon
current
studi
monitor
antibiot
resist
potenti
respiratori
bacteri
pathogen
colonis
nasopharynx
first
time
popul
determin
natur
divers
respiratori
virus
mycoplasma
chlamydia
chlamydialik
speci
associ
case
bronchiol
requir
hospit
admiss
rang
organ
includ
newli
discov
virus
treatabl
bacteria
may
contribut
chronic
lung
dysfunct
pneumonia
chlamydia
speci
increasingli
recognis
import
contributor
develop
chronic
lung
diseas
alter
lung
matur
studi
address
larg
clinic
research
gap
import
common
caus
hospitalis
indigen
infant
intervent
success
would
lead
improv
short
term
possibl
long
term
health
benefit
conclus
result
would
produc
chang
evidencebas
standard
treatment
guidelin
region
produc
similar
popul
nation
intern
final
intervent
would
also
offer
possibl
prevent
reduc
high
rate
longterm
respiratori
dysfunct
seen
australian
indigen
children
adult
risk
factor
bronchiectasi
indigen
children
includ
recurr
hospitalis
alri
sever
previou
arli
measur
durat
stay
requir
oxygen
supplement
hospitalis
context
high
burden
bronchiectasi
set
consid
import
outcom
lo
requir
oxygen
supplement
hospitalis
readmiss
within
period
length
hospitalis
common
outcom
measur
studi
bronchiol
howev
set
hospitalis
children
often
come
remot
comun
may
multipl
comorbid
influenc
discharg
thu
use
lo
defin
accord
readi
respiratori
discharg
studi
address
infant
hospitalis
bronchiol
impact
variabl
present
particularli
relat
potenti
influenc
azithromycin
acut
immun
modul
effect
limit
studi
howev
studi
design
minimis
impact
variabl
present
standardis
inclus
criteria
b
limit
enrol
within
hour
hospitalis
c
adopt
strategi
doubl
blind
placebo
control
alloc
conceal
methodolog
would
theoret
distribut
effect
equal
group
addit
event
differ
baselin
data
group
found
use
statist
method
multivari
analysi
adjust
requir
summari
given
high
burden
bronchiol
indigen
infant
age
lung
growth
critic
postnat
associ
alri
futur
lung
dysfunct
rct
azithromycin
indigen
australian
infant
hospitalis
bronchiol
potenti
short
term
gain
longterm
benefit
reduc
morbid
respiratori
ill
